Long-term secular trends in the age at menarche in Israel: a systematic literature review and pooled analysis

Gonadotropin-releasing hormone analogs treatment in girls with central precocious puberty and early fast puberty

BACKGROUND

Gonadotropin-releasing hormone analog (GnRHa) is the standard treatment for children with central precocious puberty (CPP). We assessed efficacy and safety of GnRHa treatment in girls with CPP and early fast puberty (EFP).

METHODS

This retrospective observational study included anthropometric, clinical and laboratory data retrieved from medical files of girls with CPP or EFP, treated with GnRHa and followed at a tertiary endocrine clinic during 2007-2021.

RESULTS

For both CPP (n = 144) and EFP (n = 231) groups, mean height-SDS at GnRHa initiation and termination and at the last follow-up visit was greater than mid-parental height-SDS (P < 0.001). Only among girls with EFP, mean BMI-SDS was higher at treatment termination than initiation (P = 0.025). Median ages at menarche of the CPP and EFP groups were 11.8 and 12.0 years. Menstrual irregularities were reported in 20.3% of girls with CPP and in 18.7% of those with EFP. Adverse effects to treatment were reported in 3.5% and 3.9% of girls with CPP and EFP, respectively.

CONCLUSIONS

In this large cohort, GnRHa treatment in girls with EFP was effective without significant adverse effects as in those with CPP. A randomized controlled trial is required to examine the psychological impact of GnRHa treatment of variant early puberty.

IMPACT STATEMENT

Gonadotropin-releasing hormone analog (GnRHa) is the standard treatment for central precocious puberty (CPP). We assessed efficacy and safety of GnRHa treatment in girls with early fast puberty (EFP), characterized by pubertal signs between ages 8-9 years with fast pubertal signs advancement and accelerated growth and bone maturation and in girls with CPP. We found in this large cohort that GnRHa treatment in girls with EFP was effective and safe as in those with CPP. A prospective randomized controlled trial is required to examine the psychological impact of GnRHa treatment of variant early puberty.

Trends in age at menarche from 1943 through 1989 in Taiwan: A retrospective population-based analysis

BACKGROUND

Recent studies have demonstrated a global decline in the age at menarche. Our study aimed to determine the age at menarche of Taiwanese women born between 1943 and 1989.

METHODS

Data were obtained from the Taiwan Biobank. To view the trends in age at menarche, we analyzed data from 74,799 women. The mean, standard deviation, and annual percentage change in age at menarche were calculated for birth-year cohorts.

RESULTS

The mean age at menarche of Taiwanese women born in 1943 was 14.85 years. The age at menarche decreased to 12.20 years for those born in 1989. The mean age at menarche declined by 2.65 years across the 47-year study period; hence, the reduction rate was 0.56 years per decade. This study demonstrated a downward secular trend in the age at menarche of Taiwanese women born between 1943 and 1989. This trend occurred in three stages of decline: fast (1943-1953), slow (1953-1965), and moderate (1965-1989).

CONCLUSION

The age at menarche decreased by 2.65 years among Taiwanese women born in 1943 compared with those born in 1989. This decline occurred in three stages: fast (1943-1953), slow (1953-1965), and moderate (1965-1989). This significant downward secular trend in age at menarche reflects Taiwan's socioeconomic development.

Menarche at an Earlier Age: Results from Two National Surveys of Israeli Youth, 2003 and 2016

STUDY OBJECTIVE

To assess emergent changes in the age at menarche and investigate associated factors in Israeli adolescents in 2003 and 2016.

DESIGN

Cross-sectional study.

SETTING

Two national representative school-based surveys (first and second "Mabat Youth").

PARTICIPANTS

Both surveys included female students in 7th-12th grades (ages 11-19 years). The first (N = 3328) was conducted between the years 2003 and 2004, and the second (N = 2535) from 2015 to 2016.

INTERVENTIONS

The survey questionnaire was self-administered and anthropometric measurements were performed by trained personnel.

MAIN OUTCOME MEASURES

The current age at menarche in Israeli girls was determined and independent factors (demographic, clinical, and lifestyle) examined. Changes that occurred since the past national survey more than a decade ago were documented.

RESULTS

The estimated median age at menarche declined from 13.0 (interquartile range, 12.0-14.0) years in 2003-2004 to 12.5 (interquartile range, 12.0-13.0) years in 2015-2016 (P < .0001). Jewish girls reached menarche earlier than Arab girls, but both populations experienced a similar downward trend in the past approximately 14 years. Greater body mass index, higher socioeconomic status, and immigrant status were associated with younger menarche onset (P < .001). Age at menarche remained lower in 2015-2016 vs 2003-2004, even after adjustment for these potential confounders, with a high hazard ratio (HR), which decreased as a function of survival time (t): HR_t = 15.417 × 0.813^t.

CONCLUSION

This study confirms the decline in age at menarche in Israel. Findings were associated with body mass index and population group but also indicated that other factors are likely involved.

Secular trend and social gradients in the menarcheal age of girls from eastern Poland between 1986 and 2016

The age at menarche is changing together with the development of society. The intensities of secular trends vary in different countries, regions or even towns and villages. Therefore, the objective of the paper was to assess the changes of the menarcheal age of girls in groups defined by different levels of parental education and the number of children in a family as well as the general index of socioeconomic status. The paper utilises the results of research conducted in the years 1985–1986, 2005–2006 and 2015–2016, covering 11 671 girls aged 10–16 from eastern provinces of Poland. Information about the date of birth, the date of the first period, place of residence, fathers’ and mothers’ education and the number of children in a family was collected. Research material was divided into groups stratified by mother’s education, father’s education, number of children in a family, size of place of residence and the general index of socioeconomic status (SES) was calculated. The results were processed statistically using one-way analysis of variance (ANOVA) and the Newman-Keuls method.

In all the assessed groups of girls the acceleration of maturation has been observed. Greater socio-economic differences of the menarcheal age of the respondents were observed in the years 1986–2006, whereas in the years 2006–2016 the differences were smaller. During the assessed period of 30 years, the most intensive acceleration in menarche was observed in the lowest social strata, i.e. in the daughters of parents with primary or vocational education, in those from the largest families and in those who were included in the group with the lowest SES point values. The lowest acceleration in the described indicator of development was found in girls from families with one or two children, whose parents had higher education degrees and the highest SES values.

The assessed schoolgirls still demonstrate the existence of social gradients in the menarcheal age but the gradients are smaller than 30 years ago.

A critical evaluation of comparative regulatory strategies for monitoring pharmaceuticals in recycled wastewater

Pharmaceuticals are a subset of micropollutants, present in the environment in trace concentrations. Because of their persistent nature, these chemicals are of particular concern. Little is known about how mixtures of pharmaceutical residues, found in WWTP effluents, affect the environment or public health. Yet, numerous studies show negative outcomes for both aquatic and terrestrial organisms, suggesting that they are given both to bioaccumulation and uptake in plants. Israel leads the world in effluent reuse (86%), almost exclusively utilized for purposes of agricultural irrigation. Pharmaceuticals, however, are not included in Israel's water regulatory oversight or management, essentially creating an epidemiological experiment among its citizens and environment. Globally, these compounds also are not commonly subject to monitoring or regulation. This study reviews and analyzes water policies and regulation worldwide that address the presence of pharmaceuticals in water resources, with a particular focus on Australia, Singapore, Switzerland, and the USA. Furthermore, the study investigates the reasons why these chemicals are not yet regulated in Israel. Based on a comprehensive evaluation of the data and analysis of the regulatory rationale in other countries, a list of recommended pharmaceutical standards that should be measured and monitored in Israel's wastewater treatment system is proposed. The suggested prioritization criteria should be at the heart of a new regulatory agenda for controlling pharmaceutical contamination in wastewater.

Early Menarche and Risk of Metabolic Syndrome: A Systematic Review and Meta-Analysis

BACKGROUND

The association between age at menarche and metabolic syndrome was inconsistent across studies and remains unclear. We conducted a systematic review and meta-analysis of observational studies to assess the association between age at menarche and risk of metabolic syndrome, comprehensively.

MATERIALS AND METHODS

The PubMed and ISI Web of Science databases were searched for all articles published through May 2017, and the reference lists of the retrieved articles were reviewed. Pooled relative risks (RRs) with 95% confidence intervals (CIs) were calculated using a random-effects model through combining the study-specific estimates adjusting for potential confounders.

RESULTS

Sixteen observational studies were eligible for the meta-analysis of age at menarche and metabolic syndrome, which included 13,657 cases among 51,453 subjects. The pooled RR of metabolic syndrome for the youngest versus the oldest categories of age at menarche was 1.62 (95% CI: 1.40-1.88) (p for heterogeneity = 0.01, I² = 57.3%). The analysis of 1-year decrease in age at menarche conferred a pooled RR of 1.08 (95% CI: 1.01-1.15), suggesting an 8% increase in risk of metabolic syndrome. The association between age at menarche and the risk of metabolic syndrome did not vary by study design, geographical region, number of subjects, and adjustment for confounders.

CONCLUSIONS

Our findings from the current meta-analysis suggest that earlier menarcheal age is associated with higher risk of metabolic syndrome. Age at menarche may help identify women with higher risk of metabolic syndrome. Further well-designed cohort studies are warranted to provide definitive evidence.

Declining age at menarche in Indonesia: a systematic review and meta-analysis

BACKGROUND

There has been much research on the average age at menarche onset. In higher income countries the lowering in average age at menarche is earlier than in middle-income countries and lower income countries. Indonesia as a middle-income country also has some research experience related to the average age at menarche for girls.

OBJECTIVES

This study aimed to review the lowering of the average age at menarche in Indonesia and to predict changes in average age at menarche.

METHODS

This study provides a systematic review and meta-analysis using references from Google Scholar, PubMed and Popline databases on the trend of age at menarche in Indonesia and other data sources from local and national survey reports. Metaprop command in STATA was used to do the meta-analysis of proportion of early age at menarche and time series with auto-regressive integrated moving average (ARIMA) models were used in analyzing the trend and predicting the age at menarche.

RESULTS

The results show that in Indonesia the timing of age at menarche onset has significantly lowered during the 40 years before 2010. There was meaningful decrease of age at menarche, which changed from 14.43 years [confident interval (CI) 95%: 14.42, 14.44] to 13.63 years (CI95%: 13.63, 13.64). Using the ARIMA model, mean age at menarche onset for the next year predicted that the coefficient regression would be -0.0245 (CI95%: -0.0275, -0.0215). The predicted average age at menarche shows a decrease of 0.0245 years (8-9 days) each year.

CONCLUSION

The findings indicate a significant lowering of age at menarche in Indonesian girls that has continued as a predictable trend through time until the present, paralleling recent socioeconomic changes. These predictions provide key indicators of a girl's future healthy transition from childhood into young adulthood.

Body height and age at menarche of girls from eastern Poland in the period of political transformation

Biological state of a group of people or particular individuals in various phases of ontogenesis should be treated as a positive health measure. The aim of the study was to assess the directions of changes in body height and age at menarche of girls from eastern Poland in the years 1986-2016. The data regarding 30784 students aged 10-16 living in towns and villages of the eastern parts of such regions as Podkarpackie, Lubelskie, Podlaskie, Warminsko-mazurskie and, to a slight extent, Mazowieckie were used in the study. Body height was measured and information concerning the place of living and age at menarche (yes-no) was gathered during interviews. Acceleration of body height and age at menarche was observed in girls from the east of Poland in the period of political transformation and after European Union (EU) accession, while the level of secular trends was connected with the pace of changes in the environment. Biological effects of the EU preservation of Polish agriculture and particular care of the eastern provinces of Poland reduced developmental differences between these provinces and other regions of Poland. Moreover, in the analysed period of three decades (1986-2016), the disappearance of differences in body height and age at menarche between the inhabitants of rural and urban areas was noted, which indicates larger positive socio-economic changes in the countryside. In turn, greater body height was noted in non-menstruating girls compared to their menstruating counterparts. However, in subsequent observations, smaller differences between these groups were observed.

The Impact of Adolescent Obesity on Adult Height

BACKGROUND

Childhood obesity is a major health concern. Excess adiposity during childhood affects growth and puberty. Our aim was to assess whether genetic adult height is compromised in adolescents with obesity.

METHODS

In a retrospective study of 190 obese patients followed at our Pediatric Endocrinology Institute, adult height and delta height (the difference between adult height and mid-parental height) were compared to those of 150 healthy age-matched normal-weight controls. Review of medical files yielded the relevant clinical and anthropometric data of patients, controls, and parents.

RESULTS

Of the 190 obese adolescents, 150 were morbidly obese. The median adult height of morbidly obese males was 174.3 cm, of obese males 174 cm, and of normal-weight males 176 cm (p = 0.025). Delta height of morbidly obese males was -0.5 cm, of obese males -0.8 cm, and of normal-weight males, 3 cm (p < 0.0001). The median adult height of morbidly obese females was 161.3 cm, of obese females 162.8 cm, and of normal-weight females 162 cm (p = 0.37). Delta height of morbidly obese females was -1.85 cm, of obese females -0.95 cm, and of normal-weight females 0.7 cm (p = 0.019). Impairment of potential genetic height was not associated with obesity-related comorbidities.

CONCLUSION

Adolescents with obesity showed impairment of potential genetic adult height as compared to that of normal-weight subjects.

Younger Age of Migraine Onset in Children Than Their Parents: A Retrospective Cohort Study

Migraine is known to run in families and has long been considered a strongly heritable disorder. We sought to investigate the age of onset of migraine between successive generations. Our retrospective cohort included 102 children with migraine who were referred to a pediatric headache clinic and their affected parent(s). Age at migraine onset was significantly lower in the children with a history of maternal or paternal migraine than in their mothers or fathers ( P < .001). In conclusion, data on parental history of migraine showed that children with migraine were significantly younger at first appearance of the disease than their affected parents.

Homozygous mutation in PTRH2 gene causes progressive sensorineural deafness and peripheral neuropathy

PTRH2 is an evolutionarily highly conserved mitochondrial protein that belongs to a family of peptidyl-tRNA hydrolases. Recently, patients from two consanguineous families with mutations in the PTRH2 gene were reported. Global developmental delay associated with microcephaly, growth retardation, progressive ataxia, distal muscle weakness with ankle contractures, demyelinating sensorimotor neuropathy, and sensorineural hearing loss were present in all patients, while facial dysmorphism with widely spaced eyes, exotropia, thin upper lip, proximally placed thumbs, and deformities of the fingers and toes were present in some individuals. Here, we report a new family with three siblings affected by sensorineural hearing loss and peripheral neuropathy. Autozygosity mapping followed by exome sequencing identified a previously reported homozygous missense mutation in PTRH2 (c.254A>C; p.(Gln85Pro)). Sanger sequencing confirmed that the variant segregated with the phenotype. In contrast to the previously reported patient, the affected siblings had normal intelligence, milder microcephaly, delayed puberty, myopia, and moderate insensitivity to pain. Our findings expand the clinical phenotype and further demonstrate the clinical heterogeneity related to PTRH2 variants.

Age at menarche predicts age at onset of major affective and anxiety disorders

BACKGROUND

Menarche age has been associated inconsistently with the occurrence, timing or severity of major depressive disorder (MDD), but rarely studied in women with bipolar (BDs) or anxiety disorders.

METHODS

We investigated women patients at a Sardinian mood disorder center for associations of age at menarche with age at illness onset for major affective or anxiety disorders, year of birth, and other selected factors, using bivariate comparisons and multivariate regression modeling.

RESULTS

Among women (n=1139) with DSM-IV MDD (n=557), BD-I (n=223), BD-II (n=178), or anxiety disorders (n=181), born in 1904-1998, of mean age 42.9 years, menarche age averaged 12.8 [CI: 12.7-12.9] years. Illness onset age averaged 30.9 [30.1-31.8] years, ranking: BD-I, 25.8; anxiety disorders, 28.0; BD-II, 30.3; MDD, 34.1 years. Menarche age declined secularly over birth years, and was associated with younger illness-onset, having no or fewer siblings, more psychiatrically ill first-degree relatives, living in rural environments, being suicidal, substance abuse, and being unemployed. Earlier menarche and earlier illness-onset were significantly associated for onset age groups of ≤ 20, 20-39, and > 40 years. Menarche age versus diagnosis ranked: BD-II<BD-I<anxiety disorders<MDD.

CONCLUSIONS

Age at menarche in Sardinia, as elsewhere, has declined over the past decades. It was strongly associated with age at onset of bipolar and anxiety, as well as major depressive disorders across the age range, suggesting sustained effects of biological maturational factors.

Luteinizing Hormone Secretion during Gonadotropin-Releasing Hormone Stimulation Tests in Obese Girls with Central Precocious Puberty

OBJECTIVE

Girls with precocious puberty have high luteinizing hormone (LH) levels and advanced bone age. Obese children enter puberty at earlier ages than do non-obese children. We analyzed the effects of obesity on LH secretion during gonadotropin-releasing hormone (GnRH) tests in girls with precocious puberty.

METHODS

A total of 981 subjects with idiopathic precocious puberty who had undergone a GnRH stimulation testing between 2008 and 2014 were included in the study. Subjects were divided into three groups based on body mass index (BMI). Auxological data and gonadotropin levels after the GnRH stimulation test were compared.

RESULTS

In Tanner stage 2 girls, peak stimulated LH levels on GnRH test were 11.9±7.5, 10.4±6.4, and 9.1±6.1 IU/L among normal-weight, overweight, and obese subjects, respectively (p=0.035 for all comparisons). In Tanner stage 3 girls, peak stimulated LH levels were 14.9±10.9, 12.8±7.9, and 9.6±6.0 IU/L, respectively (p=0.022 for all comparisons). However, in Tanner stage 4 girls, peak stimulated LH levels were not significantly different among normal, overweight, and obese children. On multivariate analysis, BMI standard deviation score was significantly and negatively associated with peak LH (β=-1.178, p=0.001).

CONCLUSION

In girls with central precocious puberty, increased BMI was associated with slightly lower peak stimulated LH levels at early pubertal stages (Tanner stages 2 and 3). This association was not valid in Tanner stage 4 girls.

Adolescent BMI at Northern Israel: From Trends, to Associated Variables and Comorbidities, and to Medical Signatures

The increasing prevalence of abnormal body mass index (BMI), mainly obesity, is becoming a significant public health problem. This cross-sectional study aimed to provide a comprehensive view of secular trends of BMI, and the associated socio-demographic variables and comorbidities among adolescents with abnormal BMI. Individuals of the study population were born mainly between 1970 and 1993, and were examined at 16 to 19 years of age during the years 1987 to 2010, at 1 conscription center in the northern district of Israel.The study population included 113,694 adolescents. Univariate and multivariable logistic regression models were used to investigate the associations between BMI categories, socio-demographic variables, and medical conditions.A downward trend in the prevalence of normal BMI among both male and female adolescents was obtained, while trends of overweight and obesity (in both genders) and underweight (only among females) rose. Socio-demographic variables such as religion, education, family-related parameters, residential environment, country of birth, and origin were all associated with different risks for abnormal BMI. Obesity was associated with higher risk for hyperlipidemia, endocrine disorders (only in males), knee disorders, and hypertension type I + II (in both genders). Overweight was associated with knee disorders (only in females). Underweight, exclusively in males, was associated with increased risk for endocrine disorders, proteinuria, and cardiac disorders. Hierarchical clustering analysis revealed the intricate relations between gender, BMI, and medical signatures. It brought to light novel clusters of diseases that were abundant among populations having above-normal BMI or underweight males. Furthermore, above-normal BMI was associated with a lower rate of cardiac anomalies and scoliosis/kyphosis, whereas being underweight was associated with a lower risk for hypertension and flat foot.This study provides a reliable and in-depth view of secular trends in height, weight, and BMI of male and female adolescents. It supports previous associations between abnormal BMI and demographic variables and comorbidities, while uncovering novel associations, mainly regarding medical signatures of each gender-BMI group. This might lead to better monitoring, early detection, prevention, and treatment of various conditions associated to abnormal BMI categories and gender groups.